Table 2 Summary of adverse events in the 20 patients receiving CAR T cell infusion
TEAEs (N = 20) | Any grade (%) | Grades 3–4 (%) | Grade 5 (%) |
|---|---|---|---|
Cytokine release syndrome | 95 | 45 | 0 |
Neurologic event | 65 | 30 | 10 |
Hematologic event | |||
Thrombocytopenia | 95 | 90 | 0 |
Anemia | 100 | 70 | 0 |
Neutropenia | 100 | 100 | 0 |
Non-hematologic event | |||
Diarrhea | 50 | 0 | 0 |
Abdominal pain | 15 | 0 | 0 |
Insomnia | 5 | 0 | 0 |
Headache or dizziness | 20 | 0 | 0 |
Muscle or bone pain | 25 | 0 | 0 |
Capillary leak syndromes | 30 | 0 | 0 |
Infection | 20 | 20 | 0 |
Hypotension | 25 | 5 | 0 |
Hypoxemia | 30 | 5 | 0 |
Elevated aminotransferases | 60 | 5 | 0 |
Elevated blood bilirubin | 60 | 5 | 0 |
Elevated creatinine | 0 | 0 | 0 |
Cardiovascular disorders | 0 | 0 | 0 |
Hyponatremia | 20 | 0 | 0 |
Hypokalemia | 55 | 0 | 0 |
Hypocalcemia | 65 | 0 | 0 |
Hypoalbuminemia | 50 | 0 | 0 |
Hypofibrinogenemia | 60 | 30 | 0 |
Prolonged activated partial thromboplastin time | 15 | 0 | 0 |